{"nctId":"NCT00868452","briefTitle":"Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)","startDateStruct":{"date":"2009-04"},"conditions":["Bipolar Depression"],"count":348,"armGroups":[{"label":"Lurasidone","type":"EXPERIMENTAL","interventionNames":["Drug: lurasidone + (lithium or divalproex)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo + (lithium or divalproex)"]}],"interventions":[{"name":"lurasidone + (lithium or divalproex)","otherNames":[]},{"name":"Placebo + (lithium or divalproex)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is diagnosed with bipolar I disorder, most resent episode depressed\n* Subject must have a lifetime history of at least one bipolar manic or mixed episode\n* Subject must be taking lithium or divalproex at least 28 days prior to screening\n\nExclusion Criteria:\n\n* History of nonresponse to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode\n* Subject has been hospitalized for a manic or mixed episode within 60 days prior to randomization\n* Imminent risk of suicide or injury to self, others, or property","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)","description":"MADRS total score ranges from a minimum of 0 to a maximum of 60. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.1","spread":"0.87"},{"groupId":"OG001","value":"-13.5","spread":"0.91"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)","description":"CGI-EP-S depression score ranges from a minimum of 0 to a maximum of 7. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.96","spread":"0.104"},{"groupId":"OG001","value":"-1.51","spread":"0.109"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total Score","description":"STS total score ranges from a minimum of 0 to a maximum of 30. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.5","spread":"0.78"},{"groupId":"OG001","value":"-7.0","spread":"0.81"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":183},"commonTop":["Nausea","Headache","Somnolence","Tremor","Insomnia"]}}}